Superworth

Rani Therapeutics EPS RANI

Diluted earnings per share by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$0.27
Latest quarter, Q2 FY26
−$0.04
Fiscal year 2025
−$0.59

Rani Therapeutics' earnings per share was −$0.27 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.04.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.59n/a
FY2024−$1.06n/a
FY2023−$1.33−329%
FY2022$0.58n/a
FY2021−$0.66n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.04n/a−$0.27
Q1 FY26−$0.04n/a−$0.41
Q4 FY25−$0.07n/a−$0.59
Q3 FY25−$0.12n/a−$0.79
Q2 FY25−$0.18n/a−$0.91
Q1 FY25−$0.22n/a−$0.99
Q4 FY24−$0.27n/a−$1.06
Q3 FY24−$0.24n/a−$1.06
Q2 FY24−$0.26n/a−$1.18
Q1 FY24−$0.29n/a−$1.29
Q4 FY23−$0.27n/a−$1.33
Q3 FY23−$0.36−209%−$1.41

Against its peers

Companies in Drug Manufacturers - General nearest Rani Therapeutics' size, closest first, today.

CompanyEPS, 12 monthsGrowth
RANIRani Therapeutics−$0.27
LFVNLifevantage$0.40−46% a year
SPROSpero Therapeutics$0.11
ATNMActinium Pharmaceuticals$0.36
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
PBYIPuma Biotechnology$0.52−47% a year
IRWDIronwood Pharmaceuticals$0.77
ZVRAZevra Therapeutics$0.93
CRMDCorMedix$2.13+184% a year
COLLCollegium Pharmaceutical$1.24+19% a year
Peer median$0.65

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Rani Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.